These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 25609939)

  • 1. Characterization of hepatic enzyme activity in older adults with dementia: potential impact on personalizing pharmacotherapy.
    Campbell NL; Skaar TC; Perkins AJ; Gao S; Li L; Khan BA; Boustani MA
    Clin Interv Aging; 2015; 10():269-75. PubMed ID: 25609939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetic aspects of therapy with cholinesterase inhibitors: the role of CYP2D6 in Alzheimer's disease pharmacogenetics.
    Cacabelos R; Llovo R; Fraile C; Fernández-Novoa L
    Curr Alzheimer Res; 2007 Sep; 4(4):479-500. PubMed ID: 17908053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of CYP2D6 and CYP3A4 Genotypes on the Efficacy of Cholinesterase Inhibitors in Southern Chinese Patients With Alzheimer's Disease.
    Ma SL; Tang NLS; Wat KHY; Tang JHY; Lau KH; Law CB; Chiu J; Tam CCW; Poon TK; Lin KL; Kng CPL; Kong HL; Chan TY; Chan WC; Lam LCW
    Am J Alzheimers Dis Other Demen; 2019 Aug; 34(5):302-307. PubMed ID: 31064198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytochrome P450 2D6 phenotyping in an elderly population with dementia and response to galantamine in dementia: a pilot study.
    Clarke JA; Cutler M; Gong I; Schwarz UI; Freeman D; Dasgupta M
    Am J Geriatr Pharmacother; 2011 Aug; 9(4):224-33. PubMed ID: 21803659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenomics and therapeutic prospects in dementia.
    Cacabelos R
    Eur Arch Psychiatry Clin Neurosci; 2008 Mar; 258 Suppl 1():28-47. PubMed ID: 18344047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medication adherence and tolerability of Alzheimer's disease medications: study protocol for a randomized controlled trial.
    Campbell NL; Dexter P; Perkins AJ; Gao S; Li L; Skaar TC; Frame A; Hendrie HC; Callahan CM; Boustani MA
    Trials; 2013 May; 14():125. PubMed ID: 23782591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive factors of clinical response to cholinesterase inhibitors in mild and moderate Alzheimer's disease and mixed dementia: a one-year naturalistic study.
    Miranda LF; Gomes KB; Silveira JN; Pianetti GA; Byrro RM; Peles PR; Pereira FH; Santos TR; Assini AG; Ribeiro VV; Tito PA; Matoso RO; Lima TO; Moraes EN; Caramelli P
    J Alzheimers Dis; 2015; 45(2):609-20. PubMed ID: 25589728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenetic considerations when prescribing cholinesterase inhibitors for the treatment of Alzheimer's disease.
    Cacabelos R
    Expert Opin Drug Metab Toxicol; 2020 Aug; 16(8):673-701. PubMed ID: 32520597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenomics in Alzheimer's disease.
    Cacabelos R
    Methods Mol Biol; 2008; 448():213-357. PubMed ID: 18370236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Is it personalized treatment of dementia based on the CYP2D6 gene polymorphism possible?].
    Chebotareva AD; Levin OS; Markov DD; Sychev DA; Grishina EA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2018; 118(6. Vyp. 2):90-94. PubMed ID: 30346440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship of CYP2D6, CYP3A, POR, and ABCB1 genotypes with galantamine plasma concentrations.
    Noetzli M; Guidi M; Ebbing K; Eyer S; Zumbach S; Giannakopoulos P; von Gunten A; Csajka C; Eap CB
    Ther Drug Monit; 2013 Apr; 35(2):270-5. PubMed ID: 23503455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenetic basis for therapeutic optimization in Alzheimer's disease.
    Cacabelos R
    Mol Diagn Ther; 2007; 11(6):385-405. PubMed ID: 18078356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prevalence of co-prescription of clinically relevant CYP enzyme inhibitor and substrate drugs in community-dwelling elderly Australians.
    Kerr KP; Mate KE; Magin PJ; Marley J; Stocks NP; Disler P; Pond CD
    J Clin Pharm Ther; 2014 Aug; 39(4):383-9. PubMed ID: 24702306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular pathology and pharmacogenomics in Alzheimer's disease: polygenic-related effects of multifactorial treatments on cognition, anxiety and depression.
    Cacabelos R
    Methods Find Exp Clin Pharmacol; 2007 Jul; 29 Suppl A():1-91. PubMed ID: 17957277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenomics of Alzheimer's Disease: Novel Strategies for Drug Utilization and Development.
    Cacabelos R; Naidoo V; Martínez-Iglesias O; Corzo L; Cacabelos N; Pego R; Carril JC
    Methods Mol Biol; 2022; 2547():275-387. PubMed ID: 36068470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Replication study to confirm the role of CYP2D6 polymorphism rs1080985 on donepezil efficacy in Alzheimer's disease patients.
    Albani D; Martinelli Boneschi F; Biella G; Giacalone G; Lupoli S; Clerici F; Benussi L; Ghidoni R; Galimberti D; Squitti R; Mariani S; Confaloni A; Bruno G; Mariani C; Scarpini E; Binetti G; Magnani G; Franceschi M; Forloni G
    J Alzheimers Dis; 2012; 30(4):745-9. PubMed ID: 22465999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels.
    Leon Jd; Susce MT; Pan RM; Wedlund PJ; Orrego ML; Diaz FJ
    Pharmacopsychiatry; 2007 May; 40(3):93-102. PubMed ID: 17541883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of cytochrome P4502D6 functional polymorphisms in the efficacy of donepezil in patients with Alzheimer's disease.
    Seripa D; Bizzarro A; Pilotto A; D'onofrio G; Vecchione G; Gallo AP; Cascavilla L; Paris F; Grandone E; Mecocci P; Santini SA; Masullo C; Pilotto A
    Pharmacogenet Genomics; 2011 Apr; 21(4):225-30. PubMed ID: 20859244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of multiple inhibitors or substrates of cytochrome P450 2D6 on plasma risperidone levels in patients on polypharmacy.
    Mannheimer B; von Bahr C; Pettersson H; Eliasson E
    Ther Drug Monit; 2008 Oct; 30(5):565-9. PubMed ID: 18728628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of ABT-126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: A Randomized, Double-Blind, Placebo-Controlled Study.
    Florian H; Meier A; Gauthier S; Lipschitz S; Lin Y; Tang Q; Othman AA; Robieson WZ; Gault LM
    J Alzheimers Dis; 2016; 51(4):1237-47. PubMed ID: 26967214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.